31 results about "Herpesviridae" patented technology

Bicyclic carbohydrates for the treatment of infections caused by herpseviridae, and in particular cytomegalovirus. The invention consists of the novel bicyclic carbohydrates the generic structure of which is: wherein R1 is either -Bn or -Ph; R2 and R3 are either -alkyl, -aryl, -allyl, or —H; R4 and R5 form a ring and are either —CH(Ph)- or —CH(aryl)- and X is either O, N or S.

The invention discloses an application of carex rigescens in preparing antivirus medicine. The testing shows that the carex rigescens has significant inhibitory effects to HSV-1, HSV-2, HCMV, RSV and flu A, which implicates that the carex rigescens has potential application value in remedying various virus infectious disease fields. The carex rigescens has especially important therapeutic significance for infectious diseases of herpesviridae (HSV-1, HSV-2, HCMV). The application provides an experimental basis for the carex rigescens clinically applying in remedying virus infectious diseases, provides a certain guide significance for developing medicines which can against HSV-1, HSV-2, HCMV, RSV AND Flu A virus, and has significant reference value.

To provide a medicine, particularly a pharmaceutical composition useful for preventing or treating a variety of diseases caused by infection of a virus of the Herpesviridae family. [MEANS FOR SOLVING PROBLEMS] The present invention relates to an anti-herpesvirus agent characterized by combining a helicase-primase inhibitor with a polymerase inhibitor. By combining the helicase-primase inhibitor with the polymerase inhibitor having different action mechanisms, the anti-herpesvirus agent of the present invention achieves a dramatically superior anti-herpesvirus action compared with conventional administration of a polymerase inhibitor alone. Therefore, it is particularly effective in a case in which a sufficient therapeutic effect cannot be achieved only with a polymerase inhibitor. Further, the doses of both agents can be kept low, therefore it is also possible to perform treatment by lowering the effect of an adverse reaction to be concerned.

A method is provided for the treating or prophylaxis of one or more symptoms of viral infection. The method involves the administration of citrate and / or succinate salts. The present invention also encompasses the use of citrate and / or succinate salts for the treatment or prevention of lesions or blisters, or other symptoms of infection by members of the herpes virus family.

Viral infections of the eye, and particularly viral infections in the Herpesviridae and Adenoviridae families, can be treated by administration of a pharmaceutical made up of an enzymatically active ribonuclease and a vehicle. Advantageously, the enzymatically active ribonuclease is ranpirnase, the '805 variant, rAmphinase 2, and Amphinase 2, and the vehicle is an aqueous solution.

The invention discloses a recombinant porcine pseudorabies virus strain expressing a PPV VP2 gene and a porcine IL-18 gene. The recombinant porcine pseudorabies virus (Herpesviridae) strain is numbered as CCTCC NO.V201347. The recombinant porcine pseudorabies virus PGVP218 established by the recombinant porcine pseudorabies virus strain and an IL-18-free recombinant pseudorabies virus rPRV-VP2 established in a laboratory respectively immunize rats, meanwhile a DMEM culture solution is used as a negative control and a PPV HB98 vaccine and a PRV inactivated vaccine are used as a positive control group to immunize the rats, and the immunogenicity of the recombinant virus is studied through PPV specific antibody detection, a PRV antibody neutralization test, peripheral blood T lymphocyte subpopulation determination and a attacking protection test. Results show that the recombinant virus PGVP218 is safe and effective to the rats, can induce the rats to produce specific PPV and PRV antibodies, and the number of CD4+ / CD8+T lymphocyte subpopulations is increased.

A method for obtaining a new antiviral compound with multiple action against many viruses, comprising modified highly purified yeast RNA, a pharmaceutical composition comprising such RNA, and a method for the treatment and prevention of viral disease comprising administering to a patient a composition comprising an amount effective to ameliorate the symptoms of viral disease of ribonucleic acid. The exogenous modified yeast RNA has a pronounced multiple anti-virus action in a wide range of concentrations. The modified yeast RNA is capable of inhibiting the reproduction of viruses from Orthomyxoviridae, Paramyxovirus, Hepatitis, Herpesviridae families, enterovirus and adenovirus. Also, the modified yeast RNA is capable of inhibiting the reproduction of influenza viruses, hepatitis C virus, genital herpes, human immunodeficiency virus and Coxsackie B virus.

The invention discloses a porcine pseudorabies virus strain, which is characterized in that: porcine pseudorabies virus (Herpesviridae) strain, CCTCC NO: V201314. The present invention passes the PRV / HN2012 strain to the 7th generation, and carries out the virus titer TCID to the 7th generation virus 50 The results of the determination of TCID 50 for 10 9.0 . The PRV / HN2012 strain was inoculated into mice. After 24 hours of challenge, the mice in the PRV / HN2012 strain-infected group developed neurological symptoms. After 48 hours of challenge, all the mice died, indicating that the strain has strong toxicity. Based on this, through the research on the physical and chemical characteristics of PRV / HN2012 strain, the results show that the strain is sensitive to analytical pure chloroform and belongs to enveloped virus; it has strong resistance to acid and alkali, hydrochloric acid at pH 3.0, and It was inactivated by NaOH treatment for 1 h; it had strong resistance to heat and could be inactivated by treatment in a water bath at 56°C for 1 h; it was sensitive to trypsin and had no obvious effect on its infectivity after being treated with ultraviolet light for 30 min.

The present invention generally provides for a novel NEC-targeted strategy for the development of antiherpesviral drugs as well as for a novel antiviral strategy targeting the viral-cellular nuclear egress complex (NEC) for a small molecule-based therapy or prophylaxis to control infections with human cytomegalovirus or other pathogenic viruses of the group of the Herpesviridae. Methods for screening agents / compounds / small molecules modulating / inhibiting the nuclear egress complex of Herpesviridae are provided as well. Specifically novel drug targets of the viral nuclear egress complex of viruses of the Herpesviridae are provided.

This invention relates to the field of medicine and concerns a method for the prophylaxis or treatment of diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, which envisages the use of an effective amount of a compound of general formula I or a pharmaceutically acceptable salt thereof. The invention also relates to methods for producing the aforesaid compounds, and to pharmaceutical compositions for the prophylaxis or treatment of diseases caused by RNA- and DNA-containing viruses, which contain an effective amount of a compound of general formula I or a pharmaceutically acceptable salt thereof. The invention solves the problem of providing a novel agent effective in the treatment of diseases caused by RNA-containing viruses belonging to the enterovirus genus, the metapneumovirus genus, the pneumovirus genus, the respirovirus genus or the alphacoronavirus genus, and DNA-containing viruses belonging to the adenovirus family and the herpesvirus family, and also effective in the prophylaxis and treatment of asthma exacerbations, chronic obstructive pulmonary disease, cystic fibrosis, conjunctivitis, gastroenteritis, hepatitis and myocarditis, and in the prophylaxis and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia or obstructive airways syndrome.

The present invention provides a medicament, in particular, a novel compound for preventing or treating various infections caused by herpesviridae viruses, especially infections caused by various herpes viruses, such as those caused by varicella zoster virus. Varicella (chickenpox), varicella zoster caused by multiple infections of latent varicella-zoster virus, cold sores and herpes encephalitis caused by HSV-1 infection, and genital herpes caused by HSV-2 infection. The present invention provides N-{2-[(4-substituted phenyl)amino]-2-oxoethyl}tetrahydro-2H-thiopyran-4-carbamoyl derivatives and salts thereof, wherein, phenyl The 4-position is substituted by a specific 5- or 6-membered heteroaryl group, it has effective antiviral activity, and it can be administered orally at a low dose to treat the above-mentioned diseases.

The present invention provides isolated nucleic acid molecules encoding a Herpesviridae thymidine kinase enzyme comprising one or more mutations, at least one of the mutations encoding an amino acid substitution located toward the N-terminus from a DRH nucleoside binding site which increases a biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Such mutations include amino acid substitutions within a Q substrate binding domain which increases a biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Within a further aspect, fusion proteins are provided which have both guanylate kinase and thymidine kinase biological properties. Also provided are vectors suitable for expressing such DNA molecules, as well as methods for utilizing such vectors.

The invention discloses a recombinant porcine pseudorabies virus (Herpesviridae) strain used for expression of porcine circovirus type II ORF2 gene. Preservation number of the recombinant porcine pseudorabies virus strain is CCTCC No.V201315. According to the preparation method, PCV2ORF2 gene is inserted into common carrier PG so as to construct transferring plasmid PGO; monolayer ST cells are inoculated with PRVTK<-> / gG<-> / gE<-> virus by 2h of adsorption; ST cells are transfected with plasmid PGO, wherein fusion degree of the monolayer ST cells is 80 to 90%; the recombinant porcine pseudorabies virus PGO strain is obtained by plaque purification, and is used for immunization of mouse. It is shown by results that commercial PCV2 inactivated vaccine and a group immunized by the recombinant porcine pseudorabies virus PGO strain are both capable of inducing specific humoral immune response of mouse, antibody titers of both the commercial PCV2 inactivated vaccine and the group are obviously higher than that of a group immunized by DMEM medium, and difference is significant (p<0.05). It is shown by the results of mouse lymphocyte proliferation test that specific ceullar immune response caused by the group immunized by the recombinant porcine pseudorabies virus PGO strain is more obvious than that caused by the commercial PCV2 inactivated vaccine and the group immunized by DMEM medium, and difference is obvious (p<0.05). In addition, the group immunized by the recombinant porcine pseudorabies virus PGO strain is capable of resisting severe attack by PCV2. Therefore application of the recombinant porcine pseudorabies virus strain in development of a novel PCV2 vaccine is possible.

The present invention relates to a purified nucleic acid sequence encoding a homologue of human interleukin 10 (IL-10), wherein said IL-10 homologue is expressed during the latent phase of infection by a virus of the herpesvirideae group. The present invention also relates to uses of this polypeptide, in particular for diagnosing disease states and screening for modulator and inhibitor compounds of such polypeptides and in turn the virus itself, screening for infection in vertebrates and biological tissue, cleansing of infected biological tissues, and in the treatment and / or prophylaxis and / or diagnosis of disease caused by a virus of the herpesvirideae group.

The invention relates to a medical microorganism of the herpesviridae family, in particular to a live attenuated varicella vaccine. The present invention is prepared by the following method: (1) continuously passaging MRC-5 cells; (2) inoculating into cells and continuously infecting; (3) adding culture medium; (4) washing the cell surface; (5) washing out the infection The cells are separated by centrifugation, and the vaccine solution containing a stabilizer is added for freezing; (6) the virus stock solution is obtained by ultrasonic crushing and centrifugation; (7) combined and diluted, and immediately subpackaged and freeze-dried to obtain a live attenuated varicella vaccine. The stabilizer is NaCl, KCl, KH2PO4, Na2HPO4 12H2O, sucrose, sodium glutamate, kanamycin, erythromycin and deionized water in a weight ratio of 3: 0.1: 0.2: 3.3: 50: 0.4: 0.1: 0.03:1000 dissolved in water prepared. The invention has the advantages of good safety and immunogenicity.